-
Product Insights
Liver Failure (Hepatic Insufficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Failure (Hepatic Insufficiency) - Drugs In Development, 2023’, provides an overview of the Liver Failure (Hepatic Insufficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Hepatic Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatic Injury - Drugs In Development, 2023’, provides an overview of the Hepatic Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatic Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Liver Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Liver Disease - Drugs In Development, 2023’, provides an overview of the Chronic Liver Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Liver Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute On Chronic Liver Failure (ACLF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute On Chronic Liver Failure (ACLF) - Drugs In Development, 2023’, provides an overview of the Acute On Chronic Liver Failure (ACLF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute On Chronic Liver Failure (ACLF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Alcoholic Hepatitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcoholic Hepatitis - Drugs In Development, 2023’, provides an overview of the Alcoholic Hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acute Liver Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Liver Failure - Drugs In Development, 2023’, provides an overview of the Acute Liver Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Liver Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032
Non-Alcoholic Steatohepatitis (NASH) Report Overview In the 7MM, there were 22,036,613 diagnosed prevalent cases of NASH in 2022. The market is expected to grow at an AGR of more than 2% during 2022-2032. Non-alcoholic steatohepatitis (NASH) is a subcategory of non-alcoholic fatty liver disease (NAFLD), a condition defined by fat accumulation in over 5% of cells in the liver due to causes other than alcohol consumption (Sharma and John, 2022). NASH is considered to be more severe than the non-alcoholic...
-
Product Insights
Non-Alcoholic Steatohepatitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market Report Overview The Non-Alcoholic Steatohepatitis (NASH) clinical trial market research report provides an overview of the NASH clinical trials scenario. The report provides top-line data relating to the clinical trials on NASH. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Sector Analysis
Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Non Alcoholic Fatty Liver Pipeline Drugs Analysis Overview Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease characterized by hepatic steatosis when no other causes for secondary hepatic fat accumulation (such as excessive alcohol consumption) can be identified. NAFLD ranges from the more benign condition of non-alcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which is at the more severe end of the spectrum. The NAFLD marketed and pipeline drugs market research report provides a data-driven overview of the...